Complete Filing Data
Cytek Biosciences, Inc. reported Stockholders Equity of $341.74 million for FY2025.
All values from 10-K, 20-F, and 10-Q filings on SEC EDGAR, organized by financial statement. Scroll each table horizontally for the full history. Blank cells mean Cytek Biosciences, Inc. did not report that metric for that period in XBRL — often because accounting standards changed which tag a company files under (for example, most companies moved revenue to the ASC-606 tag in 2018), so a metric may continue in a different row. Rows marked * merge those successor tags into one continuous series, preferring the audited value from the newest-standard tag where periods overlap.
Income Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Net Income * | -$66.5M | -$6.0M | -$12.1M | $2.5M | $3.0M | $19.4M |
| Net Income Loss Available To Common Stockholders Basic | -$66.5M | -$6.0M | -$12.1M | $2.6M | $0.00 | $3.2M |
| Selling And Marketing Expense | $49.4M | $49.1M | $49.1M | $33.2M | $24.7M | $15.0M |
| Revenue From Contract With Customer Excluding Assessed Tax | $201.5M | $200.5M | $193.0M | $164.0M | $128.0M | $92.8M |
| Research And Development Expense | $36.5M | $39.4M | $44.2M | $34.9M | $24.4M | $13.7M |
| Other Nonoperating Income Expense | $8.8M | $4.5M | $7.8M | $1.0M | -$1.5M | $994.0K |
| Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax | $2.2M | $1.2M | -$549.0K | -$1.6M | $832.0K | -$212.0K |
| Operating Income Loss | -$40.4M | -$20.5M | -$27.8M | -$1.8M | $9.2M | $13.7M |
| Operating Expenses | $144.8M | $131.6M | $137.3M | $102.8M | $70.0M | $38.1M |
| Nonoperating Income Expense | $10.5M | $14.8M | $12.1M | $3.1M | -$3.2M | $771.0K |
| Income Tax Expense Benefit | $36.7M | $320.0K | -$3.6M | -$1.2M | $2.9M | -$5.0M |
| Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest | -$29.8M | -$5.7M | -$15.7M | $1.3M | $5.9M | $14.4M |
| Gross Profit | $104.5M | $111.1M | $109.4M | $101.0M | $79.1M | $51.7M |
| General And Administrative Expense | $58.9M | $43.1M | $44.0M | $34.7M | $20.8M | $9.4M |
| Cost Of Goods And Services Sold | $97.0M | $89.3M | $83.6M | $63.1M | $48.8M | $41.1M |
| Comprehensive Income Net Of Tax | -$64.3M | -$4.7M | -$12.7M | $890.0K | $3.9M | $19.6M |
| Income Loss From Continuing Operations Per Diluted Share | -$0.52 | -$0.05 | -$0.09 | $0.02 | $0.00 | $0.10 |
| Income Loss From Continuing Operations Per Basic Share | -$0.52 | -$0.05 | -$0.09 | $0.02 | $0.00 | $0.11 |
| Net Income Loss Available To Common Stockholders Diluted | -$66.5M | -$6.0M | -$12.1M | $2.6M | $0.00 | $3.2M |
| Income Taxes Paid Net | $2.2M | $3.8M | $5.3M | $10.4M | $2.9M | $2.1M |
| Interest Expenses For Accretion Of Legal Settlement Liabilities | -$328.0K | -$7.2M | $1.6M | $2.2M | $1.7M | $323.0K |
| Interest Expense | $2.1M | $2.6M | $1.7M | $333.0K | ||
| Deferred Revenue Noncurrent | $18.3M | $16.1M | $15.1M | $13.1M | $9.8M | $3.5M |
| Deferred Revenue Current | $28.5M | $25.5M | $22.7M | $13.0M | $7.1M | $3.7M |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 | Q3 2021 | Q2 2021 | Q1 2021 | Q3 2020 | Q2 2020 | Q1 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income * | -$5.5M | -$5.6M | -$11.4M | $941.0K | -$10.4M | -$6.2M | -$6.5M | -$4.4M | -$6.8M | $1.6M | -$702.0K | -$2.2M | $1.4M | $2.7M | $102.0K | $6.5M | $8.1M | -$839.0K |
| Net Income Loss Available To Common Stockholders Basic | -$5.5M | -$5.6M | -$11.4M | $941.0K | -$10.4M | -$6.2M | -$6.5M | -$4.4M | -$6.8M | $1.7M | -$598.0K | -$2.0M | $346.0K | $0.00 | $0.00 | $1.4M | $1.9M | |
| Selling And Marketing Expense | $11.7M | $12.1M | $12.5M | $12.4M | $12.3M | $12.5M | $12.1M | $14.4M | $11.1M | $8.8M | $8.4M | $7.0M | $6.6M | $5.6M | $4.3M | $3.8M | $3.1M | |
| Revenue From Contract With Customer Excluding Assessed Tax | $52.3M | $45.6M | $41.5M | $51.5M | $46.6M | $44.9M | $48.0M | $49.7M | $37.1M | $40.5M | $40.2M | $35.1M | $34.4M | $30.4M | $24.3M | $25.1M | $19.1M | |
| Research And Development Expense | $9.0M | $8.8M | $9.7M | $9.9M | $10.0M | $9.8M | $11.2M | $12.1M | $10.0M | $8.7M | $8.4M | $8.0M | $6.1M | $6.2M | $5.1M | $3.4M | $2.9M | |
| Other Nonoperating Income Expense | $1.3M | $3.7M | $3.5M | $3.1M | $59.0K | $823.0K | $1.2M | $1.7M | $1.7M | -$445.0K | -$254.0K | -$374.0K | -$393.0K | -$120.0K | -$615.0K | $185.0K | $395.0K | |
| Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax | $741.0K | $603.0K | -$560.0K | $101.0K | $1.4M | -$244.0K | $165.0K | -$980.0K | -$42.0K | -$758.0K | -$683.0K | $14.0K | $34.0K | $269.0K | $202.0K | $145.0K | -$19.0K | |
| Operating Income Loss | -$9.2M | -$10.6M | -$15.0M | -$4.2M | -$8.5M | -$10.7M | -$6.4M | -$9.1M | -$12.2M | $1.4M | -$891.0K | -$2.4M | $2.9M | $3.8M | $1.1M | $6.7M | -$218.0K | |
| Operating Expenses | $36.7M | $34.5M | $35.1M | $33.3M | $34.0M | $33.7M | $33.6M | $37.3M | $33.2M | $25.5M | $25.5M | $22.5M | $18.4M | $15.9M | $13.4M | $8.9M | $8.5M | |
| Nonoperating Income Expense | $1.4M | $3.8M | $3.7M | $4.4M | $1.3M | $1.7M | $2.2M | $2.5M | $3.1M | $490.0K | -$510.0K | -$946.0K | -$822.0K | -$544.0K | -$980.0K | $186.0K | $410.0K | |
| Income Tax Expense Benefit | -$2.3M | -$1.2M | $136.0K | -$784.0K | $3.2M | -$2.8M | $2.3M | -$2.2M | -$2.2M | $224.0K | -$699.0K | -$1.1M | $655.0K | $597.0K | $50.0K | $357.0K | -$7.9M | |
| Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest | -$7.8M | -$6.8M | -$11.3M | $157.0K | -$7.2M | -$9.0M | -$4.2M | -$6.6M | -$9.0M | $1.9M | -$1.4M | -$3.3M | $2.1M | $3.3M | $152.0K | $6.9M | $192.0K | |
| Gross Profit | $27.6M | $23.9M | $20.2M | $29.0M | $25.4M | $23.0M | $27.2M | $28.2M | $21.0M | $26.9M | $24.6M | $20.2M | $21.3M | $19.7M | $14.5M | $15.6M | $8.3M | |
| General And Administrative Expense | $16.1M | $13.5M | $12.9M | $10.9M | $11.7M | $11.4M | $10.4M | $10.8M | $12.1M | $8.0M | $8.6M | $7.5M | $5.7M | $4.2M | $4.0M | $1.7M | $2.5M | |
| Cost Of Goods And Services Sold | $24.7M | $21.7M | $21.3M | $22.5M | $21.2M | $21.8M | $20.8M | $21.5M | $16.1M | $13.6M | $15.6M | $14.9M | $13.1M | $10.7M | $9.8M | $9.5M | $10.9M | |
| Comprehensive Income Net Of Tax | -$4.6M | -$5.0M | -$12.0M | $1.2M | -$9.1M | -$6.4M | -$6.3M | -$5.6M | -$6.7M | $868.0K | -$1.4M | -$2.1M | $1.5M | $2.9M | $304.0K | $6.7M | $8.1M | |
| Income Loss From Continuing Operations Per Diluted Share | -$0.04 | -$0.04 | -$0.09 | $0.01 | -$0.08 | -$0.05 | -$0.05 | -$0.03 | -$0.05 | $0.01 | $0.00 | -$0.02 | $0.00 | $0.00 | $0.00 | $0.05 | $0.06 | |
| Income Loss From Continuing Operations Per Basic Share | -$0.04 | -$0.04 | -$0.09 | $0.01 | -$0.08 | -$0.05 | -$0.05 | -$0.03 | -$0.05 | $0.01 | $0.00 | -$0.02 | $0.00 | $0.00 | $0.00 | $0.05 | $0.07 | |
| Net Income Loss Available To Common Stockholders Diluted | -$5.5M | -$5.6M | -$11.4M | $941.0K | -$10.4M | -$6.2M | -$6.5M | -$4.4M | -$6.8M | $1.7M | -$598.0K | -$2.0M | $346.0K | |||||
| Income Taxes Paid Net | $0.00 | $0.00 | $93.0K | $75.0K | $125.0K | |||||||||||||
| Interest Expenses For Accretion Of Legal Settlement Liabilities | $148.0K | $301.0K | $544.0K | $498.0K | $372.0K | |||||||||||||
| Interest Expense | $441.0K | $595.0K | $409.0K | $673.0K | $649.0K | $647.0K | $590.0K | $441.0K | $433.0K | $375.0K | $2.0K | $1.0K | ||||||
| Deferred Revenue Noncurrent | $16.3M | $16.6M | $15.7M | $14.8M | $14.1M | $15.2M | $15.0M | $16.1M | $13.0M | $10.4M | $11.0M | $7.2M | $7.7M | $6.3M | ||||
| Deferred Revenue Current | $28.7M | $28.1M | $27.7M | $25.4M | $24.0M | $23.0M | $23.0M | $20.6M | $18.1M | $12.1M | $10.0M | $12.3M | $5.9M | $4.7M |
Balance Sheet
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Stockholders Equity * | $341.7M | $395.7M | $393.1M | $425.5M | $405.4M | -$16.0M | $41.7M |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | $90.9M | $98.7M | $167.6M | $299.5M | $364.6M | $166.1M | $30.5M |
| Temporary Equity Foreign Currency Translation Adjustments | $2.2M | $1.2M | -$549.0K | -$1.6M | $832.0K | $212.0K | |
| Marketable Securities Unrealized Gain Loss | $58.0K | $97.0K | -$29.0K | $17.0K | $0.00 | $0.00 | |
| Inventory Write Down | $1.7M | $1.6M | $1.5M | $756.0K | $488.0K | $1.6M | |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | -$7.9M | -$68.9M | -$131.9M | -$65.1M | $198.5M | $135.6M | |
| Settlement Liabilities Current | $2.5M | $1.7M | $2.6M | $2.2M | $1.5M | $6.3M | |
| Retained Earnings Accumulated Deficit | -$101.7M | -$35.2M | -$29.2M | -$17.0M | -$19.6M | -$22.6M | |
| Property Plant And Equipment Net | $18.0M | $18.0M | $18.4M | $13.7M | $5.9M | $2.1M | |
| Prepaid Expense And Other Assets Current | $19.5M | $14.1M | $12.5M | $13.0M | $5.2M | $2.5M | |
| Other Liabilities Noncurrent | $2.3M | $2.4M | $2.4M | $1.6M | $1.2M | $737.0K | |
| Other Liabilities Current | $17.0M | $13.5M | $7.9M | $8.0M | $6.4M | $4.6M | |
| Other Assets Noncurrent | $6.7M | $4.8M | $3.4M | $3.0M | $1.7M | $1.1M | |
| Liabilities Current | $77.8M | $67.7M | $56.2M | $49.0M | $33.2M | $26.5M | |
| Liabilities And Stockholders Equity | $461.5M | $499.5M | $494.5M | $519.5M | $463.3M | $220.0M | |
| Liabilities | $119.8M | $103.8M | $101.4M | $93.9M | $57.9M | $41.7M | |
| Inventory Net | $48.4M | $43.9M | $60.9M | $48.2M | $32.2M | $23.0M | |
| Intangible Assets Net Excluding Goodwill | $16.8M | $20.1M | $23.1M | $4.3M | $4.7M | $274.0K | |
| Intangible Asset In Accrued Expense | $26.0K | $0.00 | $510.0K | $30.0K | $93.0K | $0.00 | |
| Goodwill | $16.7M | $16.7M | $16.2M | $10.1M | $10.1M | $476.0K | |
| Deferred Tax Assets Deferred Income | $0.00 | $33.4M | $30.5M | $20.5M | $9.2M | $7.4M | |
| Common Stock Value | $129.0K | $129.0K | $131.0K | $135.0K | $126.0K | $23.0K | |
| Cash And Cash Equivalents At Carrying Value | $90.9M | $98.7M | $167.3M | $296.6M | $364.6M | $165.2M | |
| Assets Current | $392.0M | $396.4M | $392.1M | $454.0M | $431.7M | $208.6M | |
| Assets | $461.5M | $499.5M | $494.5M | $519.5M | $463.3M | $220.0M | |
| Accumulated Other Comprehensive Income Loss Net Of Tax | $2.2M | $16.0K | -$1.3M | -$697.0K | $897.0K | $65.0K | |
| Accrued Liabilities Current | $23.4M | $21.4M | $20.0M | $21.1M | $15.3M | $9.0M | |
| Accounts Receivable Net Current | $62.5M | $60.6M | $55.9M | $48.9M | $29.8M | $17.0M | |
| Accounts Payable Trade Current | $6.4M | $5.5M | $3.0M | $4.8M | $3.0M | $2.9M |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 | Q3 2021 | Q2 2021 | Q1 2021 | Q3 2020 | Q2 2020 | Q1 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stockholders Equity * | $378.6M | $377.6M | $379.6M | $385.5M | $389.1M | $392.6M | $393.1M | $415.5M | $424.2M | $423.5M | $416.5M | $411.1M | $407.4M | $403.2M | -$11.0M | -$14.8M | -$27.4M | -$34.3M | -$42.5M |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | $93.3M | $75.5M | $95.3M | $162.3M | $177.9M | $169.1M | $163.6M | $131.5M | $132.4M | $341.5M | $349.9M | $362.5M | $376.8M | $159.8M | $168.6M | $35.5M | $35.3M | ||
| Temporary Equity Foreign Currency Translation Adjustments | $741.0K | $603.0K | -$560.0K | $101.0K | $1.4M | -$244.0K | $165.0K | -$980.0K | -$42.0K | -$758.0K | -$683.0K | $14.0K | $34.0K | $269.0K | $202.0K | $145.0K | -$19.0K | -$77.0K | |
| Marketable Securities Unrealized Gain Loss | $118.0K | -$33.0K | -$65.0K | $195.0K | -$16.0K | -$35.0K | $15.0K | -$192.0K | $152.0K | $0.00 | $0.00 | $0.00 | |||||||
| Inventory Write Down | $314.0K | $912.0K | $508.0K | $74.0K | $321.0K | ||||||||||||||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | -$3.4M | $1.5M | -$167.1M | -$2.1M | $2.5M | ||||||||||||||
| Settlement Liabilities Current | $2.2M | $2.0M | $1.7M | $2.5M | $2.5M | $2.6M | $2.6M | $1.9M | $1.9M | $2.2M | $2.1M | $1.6M | $7.4M | $7.2M | |||||
| Retained Earnings Accumulated Deficit | -$57.7M | -$52.2M | -$46.6M | -$44.8M | -$45.8M | -$35.3M | -$34.7M | -$28.2M | -$23.8M | -$20.6M | -$22.2M | -$21.6M | -$18.4M | -$19.8M | |||||
| Property Plant And Equipment Net | $18.0M | $18.4M | $17.8M | $18.5M | $18.1M | $18.2M | $17.4M | $15.6M | $15.5M | $7.8M | $7.3M | $6.5M | $5.0M | $3.9M | |||||
| Prepaid Expense And Other Assets Current | $18.5M | $15.1M | $14.5M | $12.9M | $12.1M | $13.2M | $12.0M | $10.6M | $11.1M | $13.3M | $11.2M | $8.2M | $6.1M | $6.4M | |||||
| Other Liabilities Noncurrent | $2.5M | $2.5M | $2.4M | $2.1M | $1.8M | $1.8M | $2.3M | $2.1M | $1.9M | $1.4M | $1.4M | $1.1M | $737.0K | $739.0K | |||||
| Other Liabilities Current | $16.4M | $14.7M | $12.8M | $8.8M | $7.2M | $8.2M | $7.8M | $8.4M | $10.9M | $4.9M | $5.6M | $8.4M | $2.0M | $1.4M | |||||
| Other Assets Noncurrent | $4.5M | $4.7M | $4.6M | $5.0M | $4.9M | $4.1M | $3.2M | $3.0M | $3.0M | $4.6M | $2.9M | $1.3M | $1.3M | $1.3M | |||||
| Liabilities Current | $75.2M | $73.3M | $67.7M | $62.8M | $52.4M | $55.6M | $58.7M | $53.6M | $56.5M | $41.5M | $42.4M | $42.8M | $30.0M | $28.2M | |||||
| Liabilities And Stockholders Equity | $494.9M | $493.3M | $482.6M | $491.2M | $483.7M | $492.1M | $519.4M | $525.1M | $524.6M | $499.3M | $492.8M | $485.9M | $454.3M | $230.3M | |||||
| Liabilities | $116.3M | $115.8M | $103.0M | $105.8M | $94.6M | $99.5M | $103.9M | $100.9M | $101.1M | $82.8M | $81.7M | $78.4M | $51.1M | $46.9M | |||||
| Inventory Net | $51.6M | $49.5M | $45.3M | $46.8M | $50.1M | $54.7M | $66.9M | $65.7M | $69.5M | $49.4M | $45.3M | $38.0M | $27.5M | $26.7M | |||||
| Intangible Assets Net Excluding Goodwill | $17.7M | $18.6M | $19.4M | $20.5M | $21.4M | $22.3M | $24.3M | $23.7M | $24.7M | $4.5M | $3.9M | $4.3M | $361.0K | $333.0K | |||||
| Intangible Asset In Accrued Expense | $47.0K | $46.0K | $4.0K | $40.0K | |||||||||||||||
| Goodwill | $16.7M | $16.7M | $16.7M | $16.2M | $16.2M | $16.2M | $16.5M | $19.1M | $19.1M | $10.1M | $10.1M | $10.1M | $476.0K | $476.0K | |||||
| Deferred Tax Assets Deferred Income | $38.4M | $35.8M | $33.7M | $30.8M | $29.7M | $32.7M | $24.1M | $26.4M | $23.4M | $14.0M | $11.7M | $10.7M | $7.4M | $7.4M | |||||
| Common Stock Value | $128.0K | $127.0K | $128.0K | $130.0K | $132.0K | $131.0K | $136.0K | $136.0K | $136.0K | $135.0K | $135.0K | $134.0K | $125.0K | $24.0K | |||||
| Cash And Cash Equivalents At Carrying Value | $93.3M | $75.5M | $95.3M | $162.3M | $177.9M | $168.8M | $163.6M | $131.5M | $129.5M | $341.5M | $349.9M | $362.5M | $376.8M | $159.8M | |||||
| Assets Current | $388.5M | $382.8M | $380.5M | $390.2M | $384.1M | $388.6M | $422.3M | $424.8M | $425.6M | $443.9M | $443.3M | $439.1M | $439.8M | $216.9M | |||||
| Assets | $494.9M | $493.3M | $482.6M | $491.2M | $483.7M | $492.1M | $519.4M | $525.1M | $524.6M | $499.3M | $492.8M | $485.9M | $454.3M | $230.3M | |||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | $821.0K | -$38.0K | -$609.0K | $101.0K | -$195.0K | -$1.6M | -$1.6M | -$1.8M | -$587.0K | -$530.0K | $228.0K | $911.0K | $570.0K | $536.0K | |||||
| Accrued Liabilities Current | $20.2M | $21.6M | $19.2M | $20.7M | $15.5M | $18.1M | $20.5M | $19.6M | $20.4M | $16.6M | $17.8M | $14.6M | $10.8M | $11.6M | |||||
| Accounts Receivable Net Current | $56.6M | $56.2M | $55.0M | $52.6M | $44.6M | $50.3M | $55.4M | $49.6M | $43.1M | $39.6M | $36.8M | $30.4M | $29.5M | $24.0M | |||||
| Accounts Payable Trade Current | $7.6M | $6.9M | $6.2M | $5.4M | $3.2M | $3.7M | $4.7M | $3.1M | $5.3M | $5.6M | $6.7M | $6.0M | $3.9M | $3.3M |
Cash Flow Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Share Based Compensation | $24.6M | $26.8M | $22.0M | $16.6M | $6.6M | $611.0K |
| Proceeds From Stock Options Exercised | $325.0K | $1.0M | $1.5M | $1.2M | $642.0K | $169.0K |
| Payments To Acquire Property Plant And Equipment | $4.1M | $3.5M | $4.6M | $9.7M | $4.4M | $1.5M |
| Net Cash Provided By Used In Operating Activities | -$4.7M | $25.4M | $5.3M | -$12.2M | $4.6M | $15.2M |
| Net Cash Provided By Used In Investing Activities | $10.1M | -$83.0M | -$93.9M | -$55.9M | -$21.0M | -$1.5M |
| Net Cash Provided By Used In Financing Activities | -$13.4M | -$15.8M | -$41.8M | $5.5M | $213.6M | $122.6M |
| Increase Decrease In Prepaid Deferred Expense And Other Assets | $2.7M | $2.8M | $9.5M | $19.4M | $6.3M | $8.2M |
| Increase Decrease In Legal Settlement Liabilities | -$1.1M | -$1.1M | -$298.0K | $373.0K | -$3.7M | $458.0K |
| Increase Decrease In Inventories | $5.2M | -$14.8M | -$4.3M | $17.7M | $7.1M | $5.7M |
| Increase Decrease In Deferred Revenue | $3.6M | $3.7M | $6.5M | $9.4M | $10.0M | $2.4M |
| Increase Decrease In Accrued Liabilities | $4.0M | -$817.0K | $729.0K | $7.5M | $11.0M | $3.3M |
| Increase Decrease In Accounts Receivable | -$368.0K | $5.4M | $7.3M | $19.7M | $12.4M | -$334.0K |
| Increase Decrease In Accounts Payable | $448.0K | $2.6M | -$1.8M | $1.9M | -$256.0K | $55.0K |
| Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | $109.0K | $4.5M | -$1.4M | -$2.5M | $1.3M | -$587.0K |
| Depreciation Depletion And Amortization | $7.6M | $7.2M | $6.0M | $2.5M | $1.2M | $603.0K |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|---|
| Share Based Compensation | $6.6M | $5.6M | $4.7M | $3.8M | $456.0K |
| Proceeds From Stock Options Exercised | $39.0K | $506.0K | $203.0K | $364.0K | $187.0K |
| Payments To Acquire Property Plant And Equipment | $849.0K | $567.0K | $505.0K | $780.0K | $509.0K |
| Net Cash Provided By Used In Operating Activities | -$125.0K | $4.0M | $2.9M | -$1.5M | $1.9M |
| Net Cash Provided By Used In Investing Activities | $9.5M | -$5.8M | -$168.9M | -$780.0K | -$138.0K |
| Net Cash Provided By Used In Financing Activities | -$11.5M | $1.6M | $0.00 | $364.0K | $187.0K |
| Increase Decrease In Prepaid Deferred Expense And Other Assets | $149.0K | $2.9M | $136.0K | $4.4M | $477.0K |
| Increase Decrease In Legal Settlement Liabilities | -$365.0K | -$67.0K | -$351.0K | $482.0K | $429.0K |
| Increase Decrease In Inventories | $1.5M | -$4.8M | $3.2M | $5.9M | $3.6M |
| Increase Decrease In Deferred Revenue | $1.3M | $542.0K | -$49.0K | $2.6M | $1.7M |
| Increase Decrease In Accrued Liabilities | -$2.1M | -$4.6M | $1.8M | $555.0K | $135.0K |
| Increase Decrease In Accounts Receivable | -$6.4M | -$4.2M | -$6.1M | $1.0M | -$2.2M |
| Increase Decrease In Accounts Payable | $410.0K | $615.0K | $305.0K | $2.8M | $112.0K |
| Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | -$1.2M | $1.7M | -$1.1M | -$216.0K | $481.0K |
| Depreciation Depletion And Amortization | $1.9M | $1.7M | $1.0M | $794.0K | $167.0K |
Per-Share & Share Counts
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Weighted Average Number Of Shares Outstanding Basic | 127.7M | 130.6M | 135.3M | 134.5M | 76.7M | 29.1M |
| Weighted Average Number Of Diluted Shares Outstanding | 127.7M | 130.6M | 135.3M | 138.6M | 81.5M | 32.6M |
| Common Stock Shares Outstanding | 128.6M | 129.2M | 130.7M | 135.4M | 133.7M | 31.2M |
| Common Stock Shares Issued | 128.6M | 129.2M | 130.7M | 135.4M | 133.7M | 31.2M |
| Common Stock Shares Authorized | 1.00B | 1.00B | 1.00B | 1.00B | 1.00B | 153.3M |
| Common Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 | Q3 2021 | Q2 2021 | Q1 2021 | Q3 2020 | Q2 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Weighted Average Number Of Shares Outstanding Basic | 127.5M | 126.9M | 128.3M | 131.0M | 131.4M | 130.9M | 136.2M | 135.9M | 135.5M | 134.7M | 134.4M | 133.9M | 108.3M | 31.9M | 31.6M | 28.7M | 28.5M |
| Weighted Average Number Of Diluted Shares Outstanding | 127.5M | 126.9M | 128.3M | 132.8M | 131.4M | 130.9M | 136.2M | 135.9M | 135.5M | 138.7M | 134.4M | 133.9M | 113.6M | 36.2M | 35.8M | 31.1M | 31.1M |
| Common Stock Shares Outstanding | 127.9M | 127.2M | 127.6M | 129.8M | 131.5M | 131.3M | 135.5M | 136.3M | 135.6M | 134.8M | 134.6M | 134.2M | 133.7M | 32.1M | |||
| Common Stock Shares Issued | 127.9M | 127.2M | 127.6M | 129.8M | 131.5M | 131.3M | 135.5M | 136.3M | 135.6M | 134.8M | 134.6M | 134.2M | 133.7M | 32.1M | |||
| Common Stock Shares Authorized | 1.00B | 1.00B | 1.00B | 1.00B | 1.00B | 1.00B | 1.00B | 1.00B | 1.00B | 1.00B | 1.00B | 1.00B | 1.00B | 153.3M | |||
| Common Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
Other Metrics
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | $24.6M | $26.8M | $22.0M | $16.6M | $6.6M | $611.0K |
| Investment Income Interest | $2.2M | $5.1M | $6.4M | $4.6M | $49.0K | $110.0K |
| Stock Issued During Period Value Employee Stock Purchase Plan | $325.0K | $1.0M | $1.5M | $2.9M | ||
| Capital Expenditures Incurred But Not Yet Paid | $129.0K | $177.0K | $40.0K | $67.0K | $134.0K | $0.00 |
| Litigation Reserve Noncurrent | $6.8M | $9.0M | $16.5M | $15.6M | $13.7M | $11.0M |
| Additional Paid In Capital | $441.1M | $430.8M | $423.4M | $442.9M | $423.6M | $6.5M |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 | Q3 2021 | Q2 2021 | Q1 2021 | Q3 2020 | Q2 2020 | Q1 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | $5.6M | $6.8M | $6.6M | $7.1M | $7.2M | $5.6M | $5.8M | $5.9M | $4.7M | $4.4M | $3.9M | $3.8M | $2.5M | $667.0K | $456.0K | $126.0K | $109.0K | $105.0K |
| Investment Income Interest | $573.0K | $555.0K | $508.0K | $1.4M | $1.4M | $1.4M | $1.6M | $1.2M | $2.1M | $1.6M | $391.0K | $18.0K | $12.0K | $9.0K | $10.0K | $3.0K | $16.0K | |
| Stock Issued During Period Value Employee Stock Purchase Plan | $137.0K | $66.0K | $39.0K | $146.0K | $225.0K | $506.0K | $440.0K | $483.0K | $204.0K | $224.0K | $1.2M | |||||||
| Capital Expenditures Incurred But Not Yet Paid | $234.0K | $288.0K | $139.0K | $228.0K | ||||||||||||||
| Litigation Reserve Noncurrent | $8.2M | $8.5M | $8.8M | $17.1M | $16.9M | $16.7M | $16.1M | $16.5M | $16.0M | $15.1M | $14.6M | $14.6M | $12.6M | $11.7M | ||||
| Additional Paid In Capital | $435.3M | $429.7M | $426.7M | $430.1M | $435.0M | $429.4M | $451.6M | $454.0M | $447.7M | $437.4M | $432.9M | $427.8M | $420.6M | $8.0M |
Most recent annual filing with the SEC: February 26, 2026
Data sourced from SEC EDGAR public filings as of August 7, 2026.